<DOC>
	<DOCNO>NCT01109212</DOCNO>
	<brief_summary>The purpose study determine whether bindarit effective reduce albuminuria , compare placebo , nephropathic patient treat irbesartan , background therapy .</brief_summary>
	<brief_title>The Effects Bindarit Diabetic Nephropathy</brief_title>
	<detailed_description>This pilot phase II , double-blind , multicentre , randomize , placebo-controlled , parallel group study patient DN undergo irbesartan therapy . According screen urinary albumin excretion , baseline randomization , patient categorize 2 stratum : Stratum 1 : microalbuminuria ( 20 200 μg/min , least 2 3 consecutive overnight urine sample collect screen ) Stratum 2 : macroalbuminuria ( &gt; 200 μg/min , least 2 3 consecutive overnight urine sample collect screen ) . Within stratum , patient randomly allocate 1:1 basis 2 treatment arm ( one month induction period ) : - bindarit 600MG twice day - placebo All patient treat irbesartan 300 mg/day background therapy . After 12 month treatment albuminuria evaluate primary endopoint .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>INCLUSION CRITERIA male female patient limitation race , age 30 70 year ; Type 2 diabetes define : &gt; 30 year age diagnosis ; insulin require within 6 month initial diagnosis ; history diabetic ketoacidosis ; currently treat diet , oral hypoglycemics insulin [ Brenner 2000 ] ; microalbuminuria define urinary albumin excretion , 20 200 µg/min least 2 3 overnight urine sample macroalbuminuria define urinary albumin excretion , &gt; 200 µg/min least 2 3 overnight urine sample , confirm baseline collection ; baseline albuminuria data available , patient may conditionally treat ; glycosylated haemoglobin ( Hb A1c ) &lt; 12 % Screening [ Brenner 2000 ] ; serum creatinine ≤ 3 mg/dL Screening ; normotensive patient hypertensive patient stable antihypertensive therapy last 3 month without specific contraindication angiotensin antagonist therapy ; female patient childbearing potential require negative pregnancy test use approve birth control method ; patient legally able give write informed consent trial ( sign date patient ) . EXCLUSION CRITERIA Patients enter trial follow circumstance : patient hypersensitive allergic ARBs bindarit component , positive history drug allergy ; Type 1 diabetes [ Brenner 2000 ] ; history non diabetic renal disease , include renal artery stenosis [ Brenner 2000 ] ; history heart failure enrolment [ Brenner 2000 ] ; acute myocardial infarction , coronary artery bypass graft within past one month [ Brenner 2000 ] ; cerebral vascular accident coronary angioplasty within past six month month [ Brenner 2000 ] ; Transient Ischemic Attacks ( TIA ) past 12 month [ Brenner 2000 ] ; primary aldosteronism pheocromocytoma [ Brenner 2000 ] ; severe uncontrolled hypertension ( sit diastolic blood pressure &gt; 115 and/or sit systolic blood pressure &gt; 220 mm Hg ) previous 6 month ; chronic use corticosteroid , nonsteroidal antiinflammatory drug , immunosuppressive drug , MAO inhibitor ; patient influence alcohol narcotic ; patient treat experimental drug previous 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Type 2-Diabetic Nephrophaty</keyword>
	<keyword>bindarit</keyword>
	<keyword>albuminuria</keyword>
	<keyword>MCP-1</keyword>
</DOC>